Education
About Us
Working with TipRanks
Follow Us
Zoetis (ZTS)
NYSE:ZTS
ZTS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$139.70 - $200.33
Previous CloseN/A
Volume625.10K
Average Volume (3M)2.93M
Market Cap
$65.68B
Enterprise Value$74.83B
Total Cash (Recent Filing)$1.44B
Total Debt (Recent Filing)$6.79B
Price to Earnings (P/E)25.5
Beta0.56
Next Earnings
Oct 30, 2025EPS Estimate
1.63Last Dividend Ex-Date
Jul 18, 2025Dividend Yield1.3%
Share Statistics
EPS (TTM)1.76
Shares Outstanding443,183,470
10 Day Avg. Volume2,316,738
30 Day Avg. Volume2,927,519
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue7.97
Enterprise Value/Gross Profit11.39
Enterprise Value/Ebitda18.53
Forecast
1Y Price Target
$189.00Price Target Upside27.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
Earnings PerformanceZTS delivered a solid Q2 beat on the top and bottom line, exceeding revenue expectations and showing strong growth in U.S. companion animal revenue.
Regulatory ApprovalZoetis received a positive opinion for Portela, a long-acting monoclonal antibody for cats, from the Committee for Veterinary Medicinal Products of the European Medicines Agency.
Bears Say
Competitive ThreatsBravecto Quantum is seen as a potential threat to Zoetis’s Simparica parasiticide franchise.
Product Launch ChallengesThe continued lack of traction in the US Librela launch, combined with slippage in International sales, represents an incremental risk to the growth story.
Zoetis News
ZTS FAQ
What was Zoetis’s price range in the past 12 months?
Zoetis lowest stock price was $139.70 and its highest was $200.33 in the past 12 months.
What is Zoetis’s market cap?
Zoetis’s market cap is $65.68B.
When is Zoetis’s upcoming earnings report date?
Zoetis’s upcoming earnings report date is Oct 30, 2025 which is in 44 days.
How were Zoetis’s earnings last quarter?
Zoetis released its earnings results on Aug 05, 2025. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.621 by $0.139.
Is Zoetis overvalued?
According to Wall Street analysts Zoetis’s price is currently Undervalued.
Does Zoetis pay dividends?
Zoetis pays a Quarterly dividend of $0.5 which represents an annual dividend yield of 1.3%. See more information on Zoetis dividends here
What is Zoetis’s EPS estimate?
Zoetis’s EPS estimate is 1.63.
How many shares outstanding does Zoetis have?
Zoetis has 443,183,470 shares outstanding.
What happened to Zoetis’s price movement after its last earnings report?
Zoetis reported an EPS of $1.76 in its last earnings report, beating expectations of $1.621. Following the earnings report the stock price went down -3.748%.
Which hedge fund is a major shareholder of Zoetis?
Currently, no hedge funds are holding shares in ZTS
Zoetis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$189.00 (27.53% Upside)
$189.00 (27.53% Upside)
Blogger Sentiment
Bullish
ZTS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 447.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 7.2%
Last 30 Days ▲ 7.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.34%
12-Months-Change
Fundamentals
Return on Equity
52.54%
Trailing 12-Months
Asset Growth
2.22%
Trailing 12-Months
Company Description
Zoetis
Zoetis Inc. (ZTS) is a global leader in animal health, dedicated to supporting the health and well-being of livestock and companion animals. Founded in 1952, the company develops and manufactures a wide range of veterinary medicines, vaccines, and diagnostic products. Zoetis operates in various sectors including livestock, such as cattle, swine, and poultry, as well as companion animals like dogs and cats. Its core products include parasiticides, anti-infectives, vaccines, and nutritional products, all aimed at enhancing animal health and productivity.
ZTS Company Deck
ZTS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance with significant organic revenue growth across various segments, particularly in the International domain and key franchises like Simparica and Dermatology. However, challenges such as Librela's adoption issues and tariff impacts are notable concerns. Despite these lowlights, the company's raised guidance and robust growth metrics across diverse portfolios contribute to a positive outlook.View all ZTS earnings summariesZTS Revenue Breakdown
67.83% Companion animal
31.31% Livestock
0.86% Contract manufacturing & human health
ZTS Stock 12 Month Forecast
Average Price Target
$189.00
▲(27.53% Upside)
Technical Analysis
Ownership Overview
0.07% Insiders
19.54% Mutual Funds
26.56% Other Institutional Investors
30.56% Public Companies and Individual Investors